Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, November 25, 2022 - Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of January 1, 2023.



1.     Corporate Reorganization (see attached organization chart)

New establishment of the Business Administration Office

Toward the realization of STS2030, in July 2022 we established supervisory organizations in charge of each major value chain in order to further clarify business execution responsibilities and strengthen cooperation between related departments. As the quality and speed of decision-making by each supervisory unit improves, it become increasingly important to collect and share financial and non-financial information in a timely manner, and to monitor and verify management conditions. The Business Administration Office will be newly established under the Finance & Accounting Department to combine, visualize, and analyze vast amounts of information on management resources, leading to business improvement. 

2.     Personnel Reassignments (Effective; January 1, 2023)

New (or continuing) Position


Present Position

R&D Supervisory Unit

Vice President,

Pharmacovigilance Department and President, Shionogi Pharmacovigilance Center Co., Ltd.

Masako Kaneto

Vice President,

Pharmacovigilance Department

Corporate Supervisory Unit

Senior Executive Officer,

Senior Vice President, Corporate Strategy Division

Ryuichi Kiyama

Senior Executive Officer,

Senior Vice President, Corporate Strategy Division and Corporate Planning Department

Vice President,

Corporate Planning Department

Takashi Mizukawa Shionogi Pharma Co., Ltd.

Vice President,

Sustainability Management Department

Yuka Niimi

President, Shionogi Pharmacovigilance Center Co., Ltd.

Vice President,

Finance & Accounting Department

Masako Kudou 

Vice President,

Sustainability Management Department

Senior Director,

Finance & Accounting Department, Business Administration Office

Takuji Fujiwara

Corporate Planning Department

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html